Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontunisertib dose-ranging trial in fibrostenosing Crohn's disease
2026-525197-19-00Phase 2Authorised
- Sponsor
- Agomab Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Ontunisertib with Placebo (2 arms). Primary endpoint: Endoscopic passability of ileal index stricture at Week 24. Planned start Oct 2026; status: authorised.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2026-525197-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525197-19-00.